Neurotherapeutics

Article	Citations
FTH1 Inhibits Ferroptosis Through Ferritinophagy in the 6-OHDA Model of Parkinson’s Disease	146
Central Nervous System Targets: Glial Cell Mechanisms in Chronic Pain	119
Septic-Associated Encephalopathy: a Comprehensive Review	106
Matrix Metalloproteinases in Acute Intracerebral Hemorrhage	66
Lecanemab, Aducanumab, and Gantenerumab — Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer’s Disease	61
Cell Death and Recovery in Traumatic Brain Injury	58
Neuropathology of Alzheimer’s Disease	56
Vildagliptin Attenuates Huntington’s Disease through Activation of GLP-1 Receptor/PI3K/Akt/BDNF Pathway in 3-Nitropropionic Acid Rat Model	55
Availability of Medications for the Treatment of Alcohol and Opioid Use Disorder in the USA	54
From Genetic Testing to Precision Medicine in Epilepsy	51
Current Management of Tics and Tourette Syndrome: Behavioral, Pharmacologic, and Surgical Treatments	50
Current Perspectives on Aerobic Exercise in People with Parkinson’s Disease	47
Teratoma Removal, Steroid, IVIG, Rituximab and Tocilizumab (T-SIRT) in Anti-NMDAR Encephalitis	46
Central Nervous System Targets: Inhibitory Interneurons in the Spinal Cord	46
The Local and Peripheral Immune Responses to Stroke: Implications for Therapeutic Development	44
Restless Legs Syndrome: Contemporary Diagnosis and Treatment	44
Long Noncoding RNA POU3F3 and α-Synuclein in Plasma L1CAM Exosomes Combined with β-Glucocerebrosidase Activity: Potential Predictors of Parkinson’s Disease	44
Exploratory Controlled Study of the Migraine-Suppressing Effects of Psilocybin	43
Pharmacological Inhibition of Soluble Epoxide Hydrolase as a New Therapy for Alzheimer’s Disease	42
Vascular Cognitive Impairment (VCI)	41
Aneurysmal Subarachnoid Hemorrhage: an Overview of Inflammation-Induced Cellular Changes	40
Iron and Ferroptosis as Therapeutic Targets in Alzheimer’s Disease	40
Complementary Therapies in Parkinson Disease: a Review of Acupuncture, Tai Chi, Qi Gong, Yoga, and Cannabis	39
CCR1 Activation Promotes Neuroinflammation Through CCR1/TPR1/ERK1/2 Signaling Pathway After Intracerebral Hemorrhage in Mice	39
Therapy of Parkinson’s Disease Subtypes	37

Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study	36
Effects of Cannabinoids on Sleep and their Therapeutic Potential for Sleep Disorders	34
An Update on Psychopharmacological Treatment of Autism Spectrum Disorder	34
Therapeutic Update on Huntington’s Disease: Symptomatic Treatments and Emerging Disease-Modifying Therapies	34
Targeted Perfusion Therapy in Spinal Cord Trauma	34
FG-4592 Improves Depressive-Like Behaviors through HIF-1-Mediated Neurogenesis and Synapse Plasticity in Rats	33
Medical Management and Prevention of Motor Complications in Parkinson’s Disease	33
Immunotherapies for Aging-Related Neurodegenerative Diseases—Emerging Perspectives and New Targets	32
Characterization of Selenium Compounds for Anti-ferroptotic Activity in Neuronal Cells and After Cerebral Ischemia–Reperfusion Injury	32
Neuromodulation, Specialized Proresolving Mediators, and Resolution of Pain	32
Interactions Among lncRNAs/circRNAs, miRNAs, and mRNAs in Neuropathic Pain	31
Update on Intravenous Immunoglobulin in Neurology: Modulating Neuro-autoimmunity, Evolving Factors on Efficacy and Dosing and Challenges on Stopping Chronic IVIg Therapy	29
Pituitary Adenylate Cyclase-Activating Polypeptide Attenuates Brain Edema by Protecting Blood–Brain Barrier and Glymphatic System After Subarachnoid Hemorrhage in Rats	29
Proactive Motor Functional Recovery Following Immersive Virtual Reality–Based Limb Mirroring Therapy in Patients with Subacute Stroke	28
Recombinant CCL17 Enhances Hematoma Resolution and Activation of CCR4/ERK/Nrf2/CD163 Signaling Pathway After Intracerebral Hemorrhage in Mice	28
RETRACTED ARTICLE: The Antidiabetic Metformin as an Adjunct to Antidepressants in Patients with Major Depressive Disorder: A Proof-of-Concept, Randomized, Double-Blind, Placebo-Controlled Trial	28
Lessons from Injury: How Nerve Injury Studies Reveal Basic Biological Mechanisms and Therapeutic Opportunities for Peripheral Nerve Diseases	28
Sleep Issues in Parkinson’s Disease and Their Management	28
Neurodevelopmental Disorders Commonly Presenting with Sleep Disturbances	28
Picrorhiza kurroa Prevents Memory Deficits by Inhibiting NLRP3 Inflammasome Activation and BACE1 Expression in 5xFAD Mice	28
The Sigma-1 Receptor Mediates Pridopidine Rescue of Mitochondrial Function in Huntington Disease Models	27
Advances in Therapeutic Approaches for Spontaneous Intracerebral Hemorrhage	27
Benzodiazepines, z-Hypnotics, and Risk of Dementia: Special Considerations of Half-Lives and Concomitant Use	27
Sleep and Epilepsy: a Focused Review of Pathophysiology, Clinical Syndromes, Co-morbidities, and Therapy	26
NonREM Disorders of Arousal and Related Parasomnias: an Updated Review	26
In Vivo Wireless Brain Stimulation via Non-invasive and Targeted Delivery of Magnetoelectric Nanoparticles	26
Crosstalk Among NLRP3 Inflammasome, ETBR Signaling, and miRNAs in Stress-Induced Depression-Like Behavior: a Modulatory Role for SGLT2 Inhibitors	26
HMGB1 Is a Therapeutic Target and Biomarker in Diazepam-Refractory Status Epilepticus with Wide Time Window	26
Immunogenicity and safety of mRNA COVID-19 vaccines in people with multiple sclerosis treated with different disease-modifying therapies	26
Circadian Rhythm Sleep–Wake Disorders: a Contemporary Review of Neurobiology, Treatment, and Dysregulation in Neurodegenerative Disease	26
Deep Brain Stimulation for Depression	25
P2X3-Containing Receptors as Targets for the Treatment of Chronic Pain	25
Decreased Level of Exosomal miR-5121 Released from Microglia Suppresses Neurite Outgrowth and Synapse Recovery of Neurons Following Traumatic Brain Injury	25
Autonomic Dysfunction in Parkinson’s Disease	25
Nightmare Disorder and Isolated Sleep Paralysis	25
Induction Versus Escalation in Multiple Sclerosis: A 10-Year Real World Study	25
Donepezil Protects Against Doxorubicin-Induced Chemobrain in Rats via Attenuation of Inflammation and Oxidative Stress Without Interfering With Doxorubicin Efficacy	24
Ferulic Acid Ameliorates Alzheimer’s Disease-like Pathology and Repairs Cognitive Decline by Preventing Capillary Hypofunction in APP/PS1 Mice	23
Chronic morphine-mediated upregulation of high mobility group box 1 in the spinal cord contributes to analgesic tolerance and hyperalgesia in rats	23
ω-3PUFAs Improve Cognitive Impairments Through Ser133 Phosphorylation of CREB Upregulating BDNF/TrkB Signal in Schizophrenia	23
Approach to Cognitive Impairment in Parkinson’s Disease	23
Genomics and Functional Genomics of Alzheimer’s Disease	22
Network Substrates of Centromedian Nucleus Deep Brain Stimulation in Generalized Pharmacoresistant Epilepsy	22
Reldesemtiv in Patients with Spinal Muscular Atrophy: a Phase 2 Hypothesis-Generating Study	22
Culture, Ethnicity, and Level of Education in Alzheimer’s Disease	22
Four-Repeat Tauopathies: Current Management and Future Treatments	22
Upregulation of AQP4 Improves Blood–Brain Barrier Integrity and Perihematomal Edema Following Intracerebral Hemorrhage	22
Pharmacological Management of Insomnia	22
Managing Essential Tremor	22
Direct Activation of Protein Phosphatase 2A (PP2A) by Tricyclic Sulfonamides Ameliorates Alzheimer’s Disease Pathogenesis in Cell and Animal Models	22

Axonal Charcot-Marie-Tooth Disease: from Common Pathogenic Mechanisms to Emerging Treatment Opportunities	21
The Regenerative Effect of Trans-spinal Magnetic Stimulation After Spinal Cord Injury: Mechanisms and Pathways Underlying the Effect	21
Overcoming Barriers to Parkinson Disease Trial Participation: Increasing Diversity and Novel Designs for Recruitment and Retention	20
Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study	20
Emerging Targeted Therapeutics for Genetic Subtypes of Parkinsonism	20
Disease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers	20
Neuroprotection of Exendin-4 by Enhanced Autophagy in a Parkinsonian Rat Model of α-Synucleinopathy	20
Stiff-person Syndrome and GAD Antibody-spectrum Disorders: GABAergic Neuronal Excitability, Immunopathogenesis and Update on Antibody Therapies	20
Therapeutic Approaches to the Neurologic Manifestations of COVID-19	19
Neuronal Adenylyl Cyclase Targeting Central Plasticity for the Treatment of Chronic Pain	19
Evolution of Anti-B Cell Therapeutics in Autoimmune Neurological Diseases	19
Effect of Capsaicinoids on Neurophysiological, Biochemical, and Mechanical Parameters of Swallowing Function	19
Long Noncoding RNA HOTAIRM1 Maintains Tumorigenicity of Glioblastoma Stem-Like Cells Through Regulation of HOX Gene Expression	19
The Treatment of Sleep Dysfunction in Neurodegenerative Disorders	19
Drug Repurposing: A Network-based Approach to Amyotrophic Lateral Sclerosis	19
Neuroimaging in Frontotemporal Dementia: Heterogeneity and Relationships with Underlying Neuropathology	19
Noninvasive Neuroprosthesis Promotes Cardiovascular Recovery After Spinal Cord Injury	18
Cerebellar Transcranial Direct Current Stimulation in Spinocerebellar Ataxia Type 3: a Randomized, Double-Blind, Sham-Controlled Trial	18
Mesenchymal Stem Cell (MSC)–Derived Extracellular Vesicles Protect from Neonatal Stroke by Interacting with Microglial Cells	18
IL-6 Receptor Blockade by Tocilizumab Has Anti-absence and Anti-epileptogenic Effects in the WAG/Rij Rat Model of Absence Epilepsy	18
Major Features of the 2021 WHO Classification of CNS Tumors	18
Recent Advances in Neuroimaging of Epilepsy	18
Emerging Gene and Small Molecule Therapies for the Neurodevelopmental Disorder Angelman Syndrome	17
Differential Effects of Fingolimod and Natalizumab on B Cell Repertoires in Multiple Sclerosis Patients	17
Heterogeneity in Alzheimer’s Disease Diagnosis and Progression Rates: Implications for Therapeutic Trials	17
Subcutaneous administration of β-hydroxybutyrate improves learning and memory of sepsis surviving mice	17
Management of psychiatric disorders in Parkinson’s disease	17
Treatment of Dystonia: Medications, Neurotoxins, Neuromodulation, and Rehabilitation	17
Soluble Epoxide Hydrolase Regulation of Lipid Mediators Limits Pain	17
Poly-Arginine Peptide-18 (R18) Reduces Brain Injury and Improves Functional Outcomes in a Nonhuman Primate Stroke Model	17
Targeting Gys1 with AAV‐SaCas9 Decreases Pathogenic Polyglucosan Bodies and Neuroinflammation in Adult Polyglucosan Body and Lafora Disease Mouse Models	17
Natural History Studies and Clinical Trial Readiness for Genetic Developmental and Epileptic Encephalopathies	17
A Key Role of DNA Damage-Inducible Transcript 4 (DDIT4) Connects Autophagy and GLUT3-Mediated Stemness To Desensitize Temozolomide Efficacy in Glioblastomas	16
Gene and Cell-Based Therapies for Parkinson’s Disease: Where Are We?	16
Implementation of Mobile Health Technologies in Clinical Trials of Movement Disorders: Underutilized Potential	16
Spreading Depolarizations and Subarachnoid Hemorrhage	16
Transcutaneous Spinal Neuromodulation Reorganizes Neural Networks in Patients with Cerebral Palsy	16
The Leukotriene Receptor Antagonist Montelukast Reduces Alpha-Synuclein Load and Restores Memory in an Animal Model of Dementia with Lewy Bodies	16
Antisense Oligonucleotides for the Study and Treatment of ALS	16
RETRACTED ARTICLE: Deferiprone Treatment in Aged Transgenic Tau Mice Improves Y-Maze Performance and Alters Tau Pathology	16
Surgical Treatment of Parkinson’s Disease: Devices and Lesion Approaches	16
The Use, Standardization, and Interpretation of Brain Imaging Data in Clinical Trials of Neurodegenerative Disorders	16
Treatment and Evaluation Advances in Leprosy Neuropathy	16
CREB Participates in Paclitaxel-Induced Neuropathic Pain Genesis Through Transcriptional Activation of Dnmt3a in Primary Sensory Neurons	16
Pipeline Embolization Device for Intracranial Aneurysms in a Large Chinese Cohort: Complication Risk Factor Analysis	16
CRISPR-Cas9 Gene Therapy for Duchenne Muscular Dystrophy	16
Central Nervous System Targets: Supraspinal Mechanisms of Analgesia	15
Non-pharmacological Approaches for Management of Insomnia	15
A practical guide to the pharmacological and behavioral therapy of Narcolepsy	15
Withaferin-A Treatment Alleviates TAR DNA-Binding Protein-43 Pathology and Improves Cognitive Function in a Mouse Model of FTLD	15
Current Concepts and Controversies in the Management of REM Sleep Behavior Disorder	15
Novel Immunological and Therapeutic Insights in Guillain-Barré Syndrome and CIDP	15
Considering Drug-Associated Contexts in Substance Use Disorders and Treatment Development	15
Neuroimaging, Urinary, and Plasma Biomarkers of Treatment Response in Huntington’s Disease: Preclinical Evidence with the p75NTR Ligand LM11A-31	15
Management of Tardive Syndrome: Medications and Surgical Treatments	15
Neuroprotective Activities of Long-Acting Granulocyte–Macrophage Colony-Stimulating Factor (mPDM608) in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Intoxicated Mice	15
Fabrication and Evaluation of a Xenogeneic Decellularized Nerve-Derived Material: Preclinical Studies of a New Strategy for Nerve Repair	15
The Role of the Complement System in Chronic Inflammatory Demyelinating Polyneuropathy: Implications for Complement-Targeted Therapies	15
Updates in IDH-Wildtype Glioblastoma	15
Pain Relieving and Neuroprotective Effects of Non-opioid Compound, DDD-028, in the Rat Model of Paclitaxel-Induced Neuropathy	14
Cannabidiol Modulates Behavioural and Gene Expression Alterations Induced by Spontaneous Cocaine Withdrawal	14
The Pharmacogenetics of Rituximab: Potential Implications for Anti-CD20 Therapies in Multiple Sclerosis	14
Galantamine Inhibits Aβ1–42-Induced Neurotoxicity by Enhancing α7nAChR Expression as a Cargo Carrier for LC3 Binding and Aβ1–42 Engulfment During Autophagic Degradation	14
A Novel Second-Generation EP2 Receptor Antagonist Reduces Neuroinflammation and Gliosis After Status Epilepticus in Rats	14
DREADD Activation of Pedunculopontine Cholinergic Neurons Reverses Motor Deficits and Restores Striatal Dopamine Signaling in Parkinsonian Rats	14
L-Serine Treatment is Associated with Improvements in Behavior, EEG, and Seizure Frequency in Individuals with GRIN-Related Disorders Due to Null Variants	14
Approaches to Disease Modification for Parkinson’s Disease: Clinical Trials and Lessons Learned	14
Chemotherapy-Induced Peripheral Neuropathy: Mechanisms and Therapeutic Avenues	14
Antibody Therapies in Autoimmune Encephalitis	14
Hypoglossal Nerve Stimulation Therapy for the Treatment of Obstructive Sleep Apnea	14
Modulation of the Microbiome in Parkinson’s Disease: Diet, Drug, Stool Transplant, and Beyond	13
Lentiviral Interleukin-10 Gene Therapy Preserves Fine Motor Circuitry and Function After a Cervical Spinal Cord Injury in Male and Female Mice	13
Overlapping Molecular Pathways Leading to Autism Spectrum Disorders, Fragile X Syndrome, and Targeted Treatments	13
Assessing Cannabis Demand: A Comprehensive Review of the Marijuana Purchase Task	13
Antidepressant Monotherapy and Combination Therapy with Acupuncture in Depressed Patients: A Resting-State Functional Near-Infrared Spectroscopy (fNIRS) Study	13
Autoimmune Neurological Disorders with IgG4 Antibodies: a Distinct Disease Spectrum with Unique IgG4 Functions Responding to Anti-B Cell Therapies	13
Physiology-Based Treatment of Myoclonus	13
Idiopathic Hypersomnia and Other Hypersomnia Syndromes	13
KDS2010, a Newly Developed Reversible MAO-B Inhibitor, as an Effective Therapeutic Candidate for Parkinson’s Disease	13
Cortical Mechanisms of Single-Pulse Transcranial Magnetic Stimulation in Migraine	13

Precision Therapy for Epilepsy Related to Brain Malformations	13
Pharmacological Inhibition of Brain EGFR Activation By a BBB-penetrating Inhibitor, AZD3759, Attenuates α-synuclein Pathology in a Mouse Model of α-Synuclein Propagation	13
Treating Post-traumatic Stress Disorder with Neuromodulation Therapies: Transcranial Magnetic Stimulation, Transcranial Direct Current Stimulation, and Deep Brain Stimulation	13
Structural Neuroimaging Findings Related to Adult Non-CNS Cancer and Treatment: Review, Integration, and Implications for Treatment of Cognitive Dysfunction	13
Emerging Clinical Technology: Application of Machine Learning to Chronic Pain Assessments Based on Emotional Body Maps	13
Gender-Specific Beneficial Effects of Docosahexaenoic Acid Dietary Supplementation in G93A-SOD1 Amyotrophic Lateral Sclerosis Mice	13
REM Sleep Deprivation Impairs Learning and Memory by Decreasing Brain O-GlcNAc Cycling in Mouse	13
Therapeutic Development of Apolipoprotein E Mimetics for Acute Brain Injury: Augmenting Endogenous Responses to Reduce Secondary Injury	13
Treatment of Progressive Multifocal Leukoencephalopathy Using Immune Restoration	13
Thymectomy and Risk of Generalization in Patients with Ocular Myasthenia Gravis: A Multicenter Retrospective Cohort Study	12
Targeting Therapeutic Antibodies to the CNS: a Comparative Study of Intrathecal, Intravenous, and Subcutaneous Anti-Nogo A Antibody Treatment after Stroke in Rats	12
Adjuvant High-Flow Normobaric Oxygen After Mechanical Thrombectomy for Anterior Circulation Stroke: a Randomized Clinical Trial	12
Chronic Toxoplasma gondii Infection Alleviates Experimental Autoimmune Encephalomyelitis by the Immune Regulation Inducing Reduction in IL-17A/Th17 Via Upregulation of SOCS3	12
Intranasal Dexamethasone Reduces Mortality and Brain Damage in a Mouse Experimental Ischemic Stroke Model	12
Dravet Syndrome: Novel Approaches for the Most Common Genetic Epilepsy	12
Activation of Neurogenesis in Multipotent Stem Cells Cultured In Vitro and in the Spinal Cord Tissue After Severe Injury by Inhibition of Glycogen Synthase Kinase-3	12
Comparative Effectiveness and Tolerability of the Pharmacology of Monoclonal Antibodies Targeting the Calcitonin Gene-Related Peptide and Its Receptor for the Prevention of Chronic Migraine: a Network	12
Brain–Machine Interface Induced Morpho-Functional Remodeling of the Neural Motor System in Severe Chronic Stroke	12
Emerging Therapies and Novel Targets for TDP-43 Proteinopathy in ALS/FTD	12
Diagnosis and Management of Alcohol Use Disorder in Patients with Liver Disease: Lights and Shadows	12
Nutritional Ketosis in Parkinson’s Disease — a Review of Remaining Questions and Insights	12
Chk1 Inhibition Ameliorates Alzheimer’s Disease Pathogenesis and Cognitive Dysfunction Through CIP2A/PP2A Signaling	12
Citicoline Modulates Glaucomatous Neurodegeneration Through Intraocular Pressure-Independent Control	12
Mechanisms and Treatments in Demyelinating CMT	12
Resuscitating the Globally Ischemic Brain: TTM and Beyond	11
Combination of Hydroxychloroquine and Indapamide Attenuates Neurodegeneration in Models Relevant to Multiple Sclerosis	11
The Long and the Short of Benzodiazepines and Sleep Medications: Short-Term Benefits, Long-Term Harms?	11
Blockers of Wnt3a, Wnt10a, or β-Catenin Prevent Chemotherapy-Induced Neuropathic Pain In Vivo	11
Neonatal Fc Receptor–Targeted Therapies in Neurology	11
Update on the Treatment of Ataxia: Medication and Emerging Therapies	11
Clinical and Translational Advances in Glioma Immunotherapy	11
Microglia in Alzheimer’s Disease: a Key Player in the Transition Between Homeostasis and Pathogenesis	11
Neuroimaging Biomarkers of Chronic Traumatic Encephalopathy: Targets for the Academic Memory Disorders Clinic	11
Neurokinin Receptor 1 (NK1R) Antagonist Aprepitant Enhances Hematoma Clearance by Regulating Microglial Polarization via PKC/p38MAPK/NFκB Pathway After Experimental Intracerebral Hemorrhage in Mice	11
Approaches to Gene Modulation Therapy for ALS	11
Brain-Computer Interface: Applications to Speech Decoding and Synthesis to Augment Communication	11
Tanshinone IIA Ameliorates CNS Autoimmunity by Promoting the Differentiation of Regulatory T Cells	11
Selected Clostridia Strains from The Human Microbiota and their Metabolite, Butyrate, Improve Experimental Autoimmune Encephalomyelitis	11
The Use of the Selective Imidazoline I1 Receptor Agonist Carbophenyline as a Strategy for Neuropathic Pain Relief: Preclinical Evaluation in a Mouse Model of Oxaliplatin-Induced Neurotoxicity	11
Altered Antioxidant Defenses in Drug-Naive First Episode Patients with Schizophrenia Are Associated with Poor Treatment Response to Risperidone: 12-Week Results from a Prospective Longitudinal Study	11
Monoclonal Antibodies in the Treatment of Relapsing Multiple Sclerosis: an Overview with Emphasis on Pregnancy, Vaccination, and Risk Management	11
Disease Reactivation after Fingolimod Discontinuation in Pregnant Multiple Sclerosis Patients	10
Inducible Prostaglandin E Synthase as a Pharmacological Target for Ischemic Stroke	10
Allopregnanolone Promotes Neuronal and Oligodendrocyte Differentiation In Vitro and In Vivo: Therapeutic Implication for Alzheimer’s Disease	10
Activation of LXRβ Signaling in the Amygdala Confers Anxiolytic Effects Through Rebalancing Excitatory and Inhibitory Neurotransmission upon Acute Stress	10
Medulloblastoma in the Modern Era: Review of Contemporary Trials, Molecular Advances, and Updates in Management	10
The Dysregulation of OGT/OGA Cycle Mediates Tau and APP Neuropathology in Down Syndrome	10
Novel Approaches to Prevent Epileptogenesis After Traumatic Brain Injury	10
Therapeutic Role of Neuregulin 1 Type III in SOD1-Linked Amyotrophic Lateral Sclerosis	10
Potential Risks and Benefits of Multiple Sclerosis Immune Therapies in the COVID-19 Era: Clinical and Immunological Perspectives	10
Association Between Disease-Modifying Therapies Prescribed to Persons with Multiple Sclerosis and Cancer: a WHO Pharmacovigilance Database Analysis	10
Current Management and Emerging Therapies in Multiple System Atrophy	10
Neurocritical Care: Bench to Bedside (Eds. Claude Hemphill, Michael James) Integrating and Using Big Data in Neurocritical Care	10
Transplantation of Human Neural Precursor Cells Reverses Syrinx Growth in a Rat Model of Post-Traumatic Syringomyelia	10
LRRK2 Ablation Attenuates Αlpha-Synuclein–Induced Neuroinflammation Without Affecting Neurodegeneration or Neuropathology In Vivo	10
Impact of Genetic Testing on Therapeutic Decision-Making in Childhood-Onset Epilepsies—a Study in a Tertiary Epilepsy Center	10
Magnetic Resonance Neurography: Improved Diagnosis of Peripheral Neuropathies	10
BDNF rs6265 Variant Alters Outcomes with Levodopa in Early-Stage Parkinson’s Disease	10
Receptor for Advanced Glycation End Products (RAGE) Mediates Cognitive Impairment Triggered by Pneumococcal Meningitis	10
Antibody Therapies in Autoimmune Neuromuscular Junction Disorders: Approach to Myasthenic Crisis and Chronic Management	10
Sleep Disturbances Associated with Neurological Autoimmunity	10
Myelin Biology	10
Vagus Nerve Stimulation Elicits Sleep EEG Desynchronization and Network Changes in Responder Patients in Epilepsy	10
Autoimmune Encephalitis: NMDA Receptor Encephalitis as an Example of Translational Neuroscience	10
One-Day Acceptance and Commitment Therapy Compared to Support for Depressed Migraine Patients: a Randomized Clinical Trial	10
α6GABAA Receptor Positive Modulators Alleviate Migraine-like Grimaces in Mice via Compensating GABAergic Deficits in Trigeminal Ganglia	10
Monoclonal Antibody Therapies Beyond Complement for NMOSD and MOGAD	10
A Milestone in Multiple Sclerosis Therapy: Monoclonal Antibodies Against CD20—Yet Progress Continues	10
Nervonic Acid Attenuates Accumulation of Very Long-Chain Fatty Acids and is a Potential Therapy for Adrenoleukodystrophy	10
Repetitive Transcranial Magnetic Stimulation Alleviates Neurological Deficits After Cerebral Ischemia Through Interaction Between RACK1 and BDNF exon IV by the Phosphorylation-Dependent Factor MeCP2	9
Injectable Versus Oral First-Line Disease-Modifying Therapies: Results from the Italian MS Register	9
Tuberous Sclerosis (tsc2+/-) Model Eker Rats Reveals Extensive Neuronal Loss with Microglial Invasion and Vascular Remodeling Related to Brain Neoplasia	9
Oncolytic Viral Therapy for Malignant Glioma and Their Application in Clinical Practice	9
Prolonged Use of NMDAR Antagonist Develops Analgesic Tolerance in Neuropathic Pain via Nitric Oxide Reduction-Induced GABAergic Disinhibition	9
Novel Analgesics with Peripheral Targets	9
Intranasal Insulin: a Treatment Strategy for Addiction	9
Novel Interactions Involving the Mas Receptor Show Potential of the Renin–Angiotensin system in the Regulation of Microglia Activation: Altered Expression in Parkinsonism and Dyskinesia	9
Immunoglobulin and Monoclonal Antibody Therapies in Guillain-Barré Syndrome	9
Anterior Cingulate Cortex Implants for Alcohol Addiction: A Feasibility Study	9
Therapeutic Potential of a Novel Glucagon-like Peptide-1 Receptor Agonist, NLY01, in Experimental Autoimmune Encephalomyelitis	9
Specific Expression of Glial-Derived Neurotrophic Factor in Muscles as Gene Therapy Strategy for Amyotrophic Lateral Sclerosis	9
Intranasal Allopregnanolone Confers Rapid Seizure Protection: Evidence for Direct Nose-to-Brain Delivery	9
Oral Ursodeoxycholic Acid Crosses the Blood Retinal Barrier in Patients with Retinal Detachment and Protects Against Retinal Degeneration in an Ex Vivo Model	9
Prelimbic Cortical Stimulation Improves Spatial Memory Through Distinct Patterns of Hippocampal Gene Expression in Aged Rats	9
Nusinersen in Adults with 5q Spinal Muscular Atrophy: a Systematic Review and Meta-analysis	9
Betulinic Acid Hydroxamate is Neuroprotective and Induces Protein Phosphatase 2A-Dependent HIF-1α Stabilization and Post-transcriptional Dephosphorylation of Prolyl Hydrolase 2	9
Sleep-Related Breathing Disorders: When CPAP Is Not Enough	9
Neuroprotective Roles of the Adenosine A3 Receptor Agonist AST-004 in Mouse Model of Traumatic Brain Injury	9
Repetitive Transcranial Magnetic Stimulation as a Therapeutic and Probe in Schizophrenia: Examining the Role of Neuroimaging and Future Directions	9
Predictors of Ocrelizumab Effectiveness in Patients with Multiple Sclerosis	9
Dendrimer-2PMPA Delays Muscle Function Loss and Denervation in a Murine Model of Amyotrophic Lateral Sclerosis	9
Levistolide A Attenuates Alzheimer’s Pathology Through Activation of the PPARγ Pathway	9
Brain Tumor Networks in Diffuse Glioma	9
Emotional and Neuropsychiatric Disorders Associated with Alzheimer’s Disease	9
The Arrival of Anti-CGRP Monoclonal Antibodies in Migraine	9